

Meta-analysis

Effect of vitamins C and E supplementation on *Helicobacter pylori* eradication: a meta-analysis

Guogang Li¹, Lan Li², Chaohui Yu² and Li Chen^{1*}

¹Department of Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, People's Republic of China

²Department of Gastroenterology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China

(Received 30 November 2010 – Revised 15 June 2011 – Accepted 15 June 2011 – First published online 3 August 2011)

Abstract

Vitamins C and E can act as potent antioxidants to reduce the damage caused by reactive oxygen species in gastric mucosa. Whether vitamin supplements for *Helicobacter pylori* eradication regimen could improve the rate of eradication remains uncertain. Therefore, we performed a meta-analysis to evaluate the efficacy of vitamins C and E supplementation for the eradication of *H. pylori*. Searches were conducted in the databases PubMed, EMBASE and Cochrane Library. Randomised controlled trials (RCT) that fulfilled the inclusion criteria and addressed the clinical questions of this analysis were further assessed. Of the six RCT included, five had a low methodological quality. Of the six RCT, three compared the efficacy of the eradication regimen *v.* eradication regimen plus vitamins C and E. The result of the meta-analysis showed a non-significant difference in the eradication rate of *H. pylori* between the two groups (risk ratio (RR) 0.93, $P=0.76$). Another three RCT compared the eradication regimen *v.* eradication regimen plus vitamin C only, and there too there was no significant difference in the eradication rate (RR 0.83, $P=0.32$). In conclusion, vitamins C and/or E supplements to the *H. pylori* eradication regimen could not improve the eradication rate. However, currently available data do not draw a definitive conclusion about the effectiveness of antioxidant vitamins on *H. pylori* eradication, owing to the small sample size and low-to-moderate methodological quality.

Key words: *Helicobacter pylori*; Vitamin C; Vitamin E; Eradication rate; Meta-analysis

It has been shown that infection with *Helicobacter pylori* leads to both acute and chronic inflammation in the gastric mucosa and produces reactive oxygen species in areas that it colonises. Reactive oxygen species can release harmful products accumulating in the gastric mucosa, and further cause gastric epithelial dysplasia and carcinogenesis^(1,2). Therefore, it is necessary to continuously regenerate antioxidant capacity and provide homeostasis in gastric mucosa.

Vitamin C (ascorbic acid) and vitamin E (tocopherol) can act as potent antioxidants to reduce reactive oxygen species in the gastric mucosa, as well as to inhibit nitrosoamine formation. Moreover, vitamin E has an antioxidant effect via impairing the lipid peroxidation pathway⁽³⁾. A possible relationship between *H. pylori* infection and antioxidant vitamins is under investigation. In *in vitro* assays, high concentration of

vitamin C could inhibit the growth of *H. pylori*⁽⁴⁾. In *in vivo* assays, the feeding of vitamins C and E could reduce the gastric *H. pylori* loads in animal models^(4–7). These observations make antioxidant vitamins an interesting objective in *H. pylori* eradication.

It is still unknown whether triple therapy (proton pump inhibitors (PPI) or bismuth subcitrate along with two antibiotics selected from clarithromycin, metronidazole, amoxicillin and tetracycline) supplemented with vitamins C and E could improve the rate of *H. pylori* eradication. Several experimental and clinical studies^(8–15) have shown different results. We therefore performed a meta-analysis of randomised controlled trials (RCT) to evaluate the effect of the addition of vitamins C and E to standard therapy on the eradication rate of *H. pylori* infection.

Abbreviations: PPI, proton pump inhibitor; RCT, randomised controlled trial.

* **Corresponding author:** Professor L. Chen, fax +86 571 87022776, email chenli_zju@163.com

Methods

Study design

Studies were accepted based on the following criteria: study design – RCT; study population – infection with *H. pylori* identified by rapid urease test or histological examination; intervention – drug regimen of a PPI and/or bismuth in combination with two antibiotics; comparison intervention – the same regimen plus vitamin C and/or vitamin E; and outcome – eradication of *H. pylori*. We excluded review articles, retrospective analyses, case reports as well as studies that were only reported as abstracts. If a study that met the selection criteria had missing data, we contacted the authors in an attempt to obtain these data. Approval for all study procedures was obtained from the ethics committee of the host institution.

Literature search

There were two investigators who independently searched the published RCT in the PubMed (US National Library of Medicine, Bethesda, MD, USA) (1980 to present), EMBASE (Reed Elsevier PLC, Amsterdam, The Netherlands) (1980 to present) and Cochrane Library (2011, Issue 1) databases. Bibliographies of all relevant studies and recent review articles were scanned to identify further citations. We also searched for unpublished and ongoing trials in clinicaltrials.gov and controlled-trials.com. The search terms were '*Helicobacter pylori*' and 'vitamin'. There were no language restrictions.

Data extraction

There were two independent observers who used standardised forms to independently extract data. Recorded data included the demographic characteristics of the patients, tests for confirming infection of *H. pylori*, protocol for

pharmacological therapy, eradication rate of *H. pylori* and any reported side effects of the therapy. The quality of all selected articles was ranked in accordance with the Jadad composite scale⁽¹⁶⁾. According to this scale, low-quality studies had a score of ≤ 2 and high-quality studies had a score of ≥ 3 ⁽¹⁶⁾. Allocation concealment was assessed with the classification of the Cochrane Collaboration. Disagreements remaining after contact with authors were resolved by consensus.

Statistical analysis

If several trials were available for a specific topic, we performed meta-analysis with the software RevMan 4.2.10 (provided by the Cochrane Collaboration, Oxford, UK). The risk ratio was presented with a 95% CI. We used χ^2 tests to assess statistical heterogeneity and the Higgins I^2 statistic to determine the percentage of total variation across studies due to heterogeneity. If the I^2 statistic was $\leq 50\%$, the fixed effect model was used to pool studies; otherwise, the random effects model was used.

Results

Literature search

The search strategy generated fifty-two studies. From these, we retrieved a preliminary short list of eleven papers for detailed evaluation, of which six papers were eligible for this meta-analysis (Fig. 1)^(10–15).

Study characteristics

A total of 811 participants were enrolled in the six studies (Table 1). Of the six trials, three including 323 patients were randomised to eradication therapy *v.* eradication therapy plus vitamins C and E (159 in the eradication therapy and




Fig. 1. Identification of trials for inclusion.

Table 1. Characteristics of studies included in meta-analysis

Study	Country of origin	No. of patients	Mean age (years)	Males (%)	Test for confirming infection	Test for confirming eradication
Eradication regimen/eradication regimen plus vitamins C and E						
Sezikli <i>et al.</i> (2009) ⁽¹⁰⁾	Turkey	80/80	44/43	35/30	Histology, RUT	UBT, stool antigen test
Chuang <i>et al.</i> (2002) ⁽¹¹⁾	Taiwan	49/55	35.6/37.9	39/38	Histology, culture	UBT, histology, culture
Everett <i>et al.</i> (2002) ⁽¹²⁾	UK	30/29	49/52	53/62	RUT, histology, culture	RUT, histology, culture
Eradication regimen/eradication regimen plus vitamin C						
Zojaji <i>et al.</i> (2009) ⁽¹³⁾	Iran	162/150	45/43	40/36	RUT	UBT
Chuang <i>et al.</i> (2007) ⁽¹⁴⁾	Taiwan	55/61	49.9/53.2	42/44	Histology, culture	UBT
Koçkar <i>et al.</i> (2001) ⁽¹⁵⁾	Turkey	30/30	38.9/40	40/47	Histology	Histology

RUT, rapid urease test; UBT, urea breath test.

164 in the eradication therapy plus vitamins C and E group)^(10–12). There were no significant differences between the two groups with regard to age, sex and endoscopic or pathological diagnosis. Another three trials were included for the analysis of eradication therapy *v.* eradication therapy plus only vitamin C (247 patients in the eradication therapy and 241 patients in the eradication therapy plus vitamin C group)^(13–15). The demographic characteristics of the two groups also had no differences.

Quality of methods

Table 2 showed the quality of the included studies as assessed by the Jadad score, and allocation concealment was assessed with the classification of the Cochrane collaboration. Of the six included RCT, five^(10,11,13–15) had a high risk of bias. None of the trials reported on the generation of a randomisation list. Only one trial performed double-blind outcome assessment and adequate allocation concealment⁽¹²⁾. All trials had a clear explanation for withdrawals and dropouts in each group.

Eradication regimen v. eradication regimen plus vitamins C and E

A total of three RCT compared the efficacy of the eradication regimen *v.* eradication regimen plus vitamins C and E in patients with *H. pylori* infection^(10–12). Of the three trials, one⁽¹⁰⁾ used PPI, bismuth subcitrate plus two antibiotics as eradication therapy; the other two^(11,12) used PPI or bismuth subcitrate plus two antibiotics. The daily dosage of vitamin C in different trials varied from 400 to 1000 mg. Vitamin E

was used at a dose of 100–400 mg/d. In the different trials, eradication therapy was continued for 1–2 weeks followed by vitamin supplementation for 2–6 weeks (Table 3).

In the eradication therapy group, *H. pylori* eradication was achieved in 56.67–60% of patients. In the eradication therapy plus vitamins C and E group, the eradication rate varied between 40 and 91.25% during the study period. Available information on the eradication rate for three studies was included in the meta-analysis. Our meta-analysis detected a non-significant difference in the eradication rate of *H. pylori* (eradication regimen 59.12% *v.* eradication regimen plus vitamins C and E 69.51%, risk ratio 0.93 (95% CI 0.56, 1.53), *P*=0.76, Fig. 2), showing that vitamins C and E supplements to the *H. pylori* eradication regimen might have no effect on the treatment of *H. pylori* infection. The test for heterogeneity indicated that the studies were significantly heterogeneous, so the random effects model was used.

Eradication regimen v. eradication regimen plus vitamin C

A total of three RCT compared the eradication regimen *v.* eradication regimen plus vitamin C only in patients with *H. pylori* infection^(13–15). Of the three trials, one⁽¹³⁾ used PPI, bismuth subcitrate plus two antibiotics as eradication therapy; the other two^(14,15) used PPI plus two antibiotics. The mean dose of vitamin C varied from 500 to 1000 mg/d. In different trials, the patients received the eradication therapy or eradication therapy plus vitamin C for 1 or 2 weeks (Table 3).

In the eradication therapy group, the eradication rate of *H. pylori* varied from 48.77 to 66.67%. In the eradication therapy plus vitamin C group, the eradication rate in

Table 2. Methodological quality of trials included in meta-analysis

Study	Randomisation method	Blind	Explanation for withdrawals/dropouts	Jadad score	Allocation concealment	ITT analysis
Eradication regimen/eradication regimen plus vitamins C and E						
Sezikli <i>et al.</i> (2009) ⁽¹⁰⁾	Unclear	None	Yes	2	Unclear	Yes
Chuang <i>et al.</i> (2002) ⁽¹¹⁾	Unclear	None	Yes	2	Unclear	Yes
Everett <i>et al.</i> (2002) ⁽¹²⁾	Unclear	Double-blind	Yes	4	Adequate	Yes
Eradication regimen/eradication regimen plus vitamin C						
Zojaji <i>et al.</i> (2009) ⁽¹³⁾	Unclear	None	Yes	2	Unclear	Yes
Chuang <i>et al.</i> (2007) ⁽¹⁴⁾	Unclear	None	Yes	2	Unclear	Yes
Koçkar <i>et al.</i> (2001) ⁽¹⁵⁾	Unclear	None	Yes	2	Unclear	Yes

ITT, intention-to-treat.

Table 3. Intervention features and results of studies included in meta-analysis

Study	Eradication regimen	Vitamin C dose (mg/d)	Vitamin E dose (mg/d)	Therapy duration (weeks)	ITT eradication (%)	
					Without vitamin	With vitamin
Eradication regimen/eradication regimen plus vitamins C and E						
Sezikli <i>et al.</i> (2009) ⁽¹⁰⁾	Lansoprazole + amoxicillin + clarithromycin + bismuth	1000	400	Eradication regimen: 2 Vitamins: 30 d	60	91.25
Chuang <i>et al.</i> (2002) ⁽¹¹⁾	Lansoprazole + amoxicillin + metronidazole	500 (1 week) to 250 (6 weeks)	400 (1 week) to 200 (6 weeks)	Eradication regimen: 1 Vitamins: 7	59.18	40
Everett <i>et al.</i> (2002) ⁽¹²⁾	Bismuth + tetracycline + metronidazole	400	100	Eradication regimen: 2 Vitamins: 4	56.67	65.52
Eradication regimen/eradication regimen plus vitamin C						
Zojaji <i>et al.</i> (2009) ⁽¹³⁾	Omeprazole + amoxicillin + metronidazole + bismuth	500	–	Eradication regimen: 2 Vitamin: 2	48.77	78
Chuang <i>et al.</i> (2007) ⁽¹⁴⁾	Omeprazole + amoxicillin + clarithromycin	1000	–	Eradication regimen: 1 Vitamin: 1	63.63	78.69
Koçkar <i>et al.</i> (2001) ⁽¹⁵⁾	Lansoprazole + amoxicillin + clarithromycin	1000	–	Eradication regimen: 2 Vitamin: 2	66.67	50

ITT, intention-to-treat.

individual trials varied from 50 to 78.69%. We performed a meta-analysis to evaluate the eradication rate as the outcome measure for all three trials. No difference was observed between the two groups (eradication regimen 54.25% *v.* eradication regimen plus vitamin C 74.69%, risk ratio 0.83 (95% CI 0.58, 1.19), *P*=0.32, Fig. 3). The test for heterogeneity indicated that the studies were statistically heterogeneous, so the random effects model was used to pool studies.

Adverse events

The most frequent adverse effects were nausea, diarrhoea, headache and skin rash. Because of a skin rash, one patient in the eradication therapy plus vitamins C and E group had to discontinue the therapy⁽¹¹⁾. There were no serious adverse events. Most of the patients tolerated these drugs well.

Discussion

Helicobacter pylori infections play a major role in the development of peptic ulcers, chronic gastritis, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma⁽¹⁷⁾. Approximately 50% of the world's population is infected

with *H. pylori*⁽¹⁸⁾. Eradication criteria defined in the Maastricht III Report is now commonly used for *H. pylori* eradication⁽¹⁹⁾. However, increasing antimicrobial resistance, falling eradication rates, high treatment costs and drugs side effects have led to the necessity of the development of new treatment modalities.

The microenvironment created by *H. pylori* in the gastric mucosa protected these bacteria from gastric acid and a host of defensive mechanisms. Moreover, *H. pylori* infection under this microenvironment promotes oxidative DNA damage to gastric mucosa by reactive oxygen species⁽²⁰⁾. Therefore, it is necessary to develop remedies combining with antibiotics for impairing this microenvironment. Some studies and clinical experiments suggest that vitamins C and E could inhibit the growth of *H. pylori* and increase the effects of the antibiotics^(4–7,21,22). There are several suggestions for the mechanism of vitamins C and E. First, vitamins C and E impair the microenvironment of *H. pylori* by attenuating oxidative stress and oxidative DNA damage in the gastric mucosa, thus inhibiting the growth of *H. pylori*. Second, vitamins C and E may strengthen the immune system and provide an appropriate environment for antibiotics to affect the bacteria. However, the opposite has also been observed by




Fig. 2. Forest plots for eradication rate comparison: eradication regimen *v.* eradication regimen plus vitamins C and E. RR, risk ratio.




Fig. 3. Forest plots for eradication rate comparison: eradication regimen v. eradication regimen plus vitamin C. RR, risk ratio.

several investigators. Kamiji & Oliveira⁽⁹⁾ found that the administration of vitamin C did not alter the bacterial load in the *H. pylori*-infected patients. Similarly, a high dose of vitamin C had not been shown to protect vitamin C-deficient gulo(-/-) mice against *H. pylori*-induced gastritis and gastric premalignancy⁽²³⁾. Therefore, whether the eradication regimen supplemented with vitamins C and E could improve the *H. pylori* eradication rate remains uncertain.

The purpose of the present review was to provide additional insight into the options for treating the infection of *H. pylori*, focusing on the effect of the addition of vitamins C and E to the eradication regimen in the *H. pylori*-infected patients. Few RCT have tested the effects of antioxidant vitamins for *H. pylori*, and none of the existing trials was methodologically rigorous. This is the first meta-analysis to compile all available RCT comparing the eradication regimen with the eradication regimen plus antioxidant vitamins for *H. pylori* infection. The present results showed that vitamins C and/or E supplements to the *H. pylori* eradication regimen had no effect on improving the *H. pylori* eradication rate. Of the six RCT included in our meta-analysis, two trials demonstrated that the treatment plus vitamins was superior to the treatment alone. The reasons for this discrepancy were not clear, other than the possibility of the addition of bismuth subcitrate to triple therapy in these two trials. High heterogeneity was found among the trials, limiting the quality of meta-analysis; hence, we provided a more conservative estimate of a treatment effect by using a random effect model. The present results should be interpreted with some caution while considering the relatively few trials and significant heterogeneity.

The reasons that the addition of vitamins C and E to the eradication regimen did not increase *H. pylori* eradication rate might be as follows: first, antioxidant vitamin supplements might have either a beneficial or a harmful effect for *H. pylori* eradication. It was reported that vitamin C could mediate the formation of genotoxins from lipid hydroperoxides in the absence of transition metal ions⁽²⁴⁾. Second, the observation that vitamin C inhibits the *in vitro* growth of *H. pylori* at concentrations of 2048, 512 and 128 µg/ml at pH values of 7.4, 6.0 and 5.5 is of particular interest, and the inhibitory activity of vitamin C might be pH dependent⁽⁴⁾. Therefore, PPI might have a negative effect on the *H. pylori* inhibitory activity of vitamin C through elevating intra-gastric pH.

The eradication rate of *H. pylori* was poor in some studies included in our meta-analysis⁽¹⁰⁻¹⁵⁾. Several factors, including patient compliance, bacterial density and antimicrobial susceptibility of *H. pylori*, contributed to the unsatisfying eradication rate of the standard treatment. A triple regimen without the use of PPI in the trial by Everett *et al.*⁽¹²⁾ could be another reason for explaining the low eradication rate.

This meta-analysis has several limitations. The studies included are of relatively poor quality, with five of the six studies having a Jadad score of <3. None of the RCT described the generation of a random sequence. Only one study included in this meta-analysis performed double blinding and allocation concealment. Thus, the reliability of the evidence presented in the present study is clearly low. An additional limitation is the small number of available studies and an overall sample size of fewer than 1000 patients included in the meta-analysis, which does not allow for conclusive statements on the effectiveness of vitamin supplements to *H. pylori* eradication regimen for treating *H. pylori* infection. Considering the low and moderate quality of evidence and limited data, ongoing and future trials for the effect of vitamins on *H. pylori* eradication might affect the present results.

In summary, based on the available data, vitamins C and/or E supplements to *H. pylori* eradication regimens could not improve the eradication rate of *H. pylori*. However, these data do not allow for definitive conclusions about the effectiveness of antioxidant vitamins on *H. pylori* eradication, owing to the small sample size and low-to-moderate methodological quality. In future studies, more rigorous double-blind and larger RCT to study the effects of vitamin supplements to *H. pylori* eradication regimen are required. The findings from our meta-analysis may allow for a better planning of those trials, sample size estimation, definition of treatment protocol and selection of trial end points.

Acknowledgements

G. L., L. L. and L. C. conceived the study design; L. L. and C. Y. searched and selected the trials, extracted, analysed and interpreted the data; G. L., L. L. and L. C. drafted the manuscript. All authors read and approved the final version of the manuscript. The authors have no conflicts of interest.

The study was supported by the science and technology plan projects of Zhejiang Province (grant nos 2008C33053 and 2009C33010).

References

1. Sasazuki S, Hayashi T, Nakachi K, *et al.* (2008) Protective effect of vitamin C on oxidative stress: a randomized controlled trial. *Int J Vitam Nutr Res* **78**, 121–128.
2. Calvino-Fernández M, Benito-Martínez S & Parra-Cid T (2008) Oxidative stress by *Helicobacter pylori* causes apoptosis through mitochondrial pathway in gastric epithelial cells. *Apoptosis* **13**, 1267–1280.
3. Sugimoto N, Yoshida N, Nakamura Y, *et al.* (2006) Influence of vitamin E on gastric mucosal injury induced by *Helicobacter pylori* infection. *Biofactors* **28**, 9–19.
4. Zhang HM, Wakisaka N, Maeda O, *et al.* (1997) Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: *Helicobacter pylori*. *Cancer* **80**, 1897–1902.
5. Wang X, Willén R & Wadström T (2000) Astaxanthin-rich algal meal and vitamin C inhibit *Helicobacter pylori* infection in BALB/cA mice. *Antimicrob Agents Chemother* **44**, 2452–2457.
6. Sjunnesson H, Sturegard E, Willen R, *et al.* (2001) High intake of selenium, beta-carotene, and vitamins A, C, and E reduces growth of *Helicobacter pylori* in the guinea pig. *Comp Med* **51**, 418–423.
7. Sun YQ, Girgensone I, Leanderson P, *et al.* (2005) Effects of antioxidant vitamin supplements on *Helicobacter pylori*-induced gastritis in Mongolian gerbils. *Helicobacter* **10**, 33–42.
8. Kaboli SA, Zojaji H, Mirsattari D, *et al.* (2009) Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazole triple regimen on *Helicobacter pylori* eradication. *Acta Gastroenterol Belg* **72**, 222–224.
9. Kamiji MM & Oliveira RB (2005) Effect of vitamin C administration on gastric colonization by *Helicobacter pylori*. *Arq Gastroenterol* **42**, 167–172.
10. Sezikli M, Cetinkaya ZA, Sezikli H, *et al.* (2009) Oxidative stress in *Helicobacter pylori* infection: does supplementation with vitamins C and E increase the eradication rate? *Helicobacter* **14**, 280–285.
11. Chuang CH, Sheu BS, Huang AH, *et al.* (2002) Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible *Helicobacter pylori* infection. *Helicobacter* **7**, 310–316.
12. Everett SM, Drake IM, White KL, *et al.* (2002) Antioxidant vitamin supplements do not reduce reactive oxygen species activity in *Helicobacter pylori* gastritis in the short term. *Br J Nutr* **87**, 3–11.
13. Zojaji H, Talaie R, Mirsattari D, *et al.* (2009) The efficacy of *Helicobacter pylori* eradication regimen with and without vitamin C supplementation. *Dig Liver Dis* **41**, 644–647.
14. Chuang CH, Sheu BS, Kao AW, *et al.* (2007) Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for *Helicobacter pylori* eradication. *Hepatogastroenterology* **54**, 320–324.
15. Koçkar C, Oztürk M & Bavbek N (2001) *Helicobacter pylori* eradication with beta carotene, ascorbic acid and allicin. *Acta Medica (Hradec Kralove)* **44**, 97–100.
16. Kjaergard LL, Villumsen J & Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med* **135**, 982–989.
17. Kandulski A, Selgrad M & Malfertheiner P (2008) *Helicobacter pylori* infection: a clinical overview. *Dig Liver Dis* **40**, 619–626.
18. Go MF (2002) Review Article: natural history and epidemiology of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* **16**, Suppl. 1, 3–15.
19. Suzuki H, Nishizawa T & Hibi T (2010) *Helicobacter pylori* eradication therapy. *Future Microbiol* **5**, 639–648.
20. Naito Y & Yoshikawa T (2002) Molecular and cellular mechanisms involved in *Helicobacter pylori*-induced inflammation and oxidative stress. *Free Radic Biol Med* **33**, 323–336.
21. Sasazuki S, Sasaki S, Tsubono Y, *et al.* (2003) The effect of 5-year vitamin C supplementation on serum pepsinogen level and *Helicobacter pylori* infection. *Cancer Sci* **94**, 378–382.
22. Jarosz M, Dzieniszewski J, Dabrowska-Ufniarz E, *et al.* (1998) Effects of high dose vitamin C treatment on *Helicobacter pylori* infection and total vitamin C concentration in gastric juice. *Eur J Cancer Prev* **7**, 449–454.
23. Lee CW, Wang XD, Chien KL, *et al.* (2008) Vitamin C supplementation does not protect L-gulonolactone oxidase-deficient mice from *Helicobacter pylori*-induced gastritis and gastric premalignancy. *Int J Cancer* **122**, 1068–1076.
24. Lee SH, Oe T & Blair IA (2001) Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. *Science* **292**, 2083–2086.